House Committee on Energy and Commerce

All Updates

Jul 15, 2026

Chairmen Guthrie and Hudson Announce Hearing on Protecting Communications Networks and Improving Connectivity

WASHINGTON, D.C. - Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Richard Hudson (NC-09), Chairman of the Subcommittee on Communications and Technology, announced a hearing titled Legislative Hearing on Protecting Communications Networks and Improving Connectivit_y._

"Bad actors, whether adversarial nations or agents of chaos, often seek to exploit communications networks to carry out their objectives, so it is imperative that we in Congress do our part to secure our nation's communications networks and ensure that every American has access to the reliable connectivity that underpins the digital economy," said Chairmen Guthrie and Hudson. "This hearing will give Members the opportunity to examine legislation that aims to protect Americans from foreign threats, such as China, cut down on scammers and bad actors using illegal robocalls to target Americans, and expand access to the reliable broadband needed for the 21 st Century economy. We look forward to discussing and examining these bipartisan proposals as we work to keep families and businesses safe and connected."

Subcommittee on Communications and Technology hearing titled Legislative Hearing on Protecting Communications Networks and Improving Connectivity.

WHAT: Subcommittee on Communications and Technology hearing to consider legislation to protect communications networks and improve connectivity.

DATE: Wednesday, July 22, 2026
TIME: 2:00 PM ET
LOCATION: 2123 Rayburn House Office Building

The hearing will focus on the following bills:

H.R. 9129, GUARD Act (Reps. Moolenaar and McClellan)
H.R. 6152, Foreign Robocall Elimination Act (Reps. McDowell and Morrison)
H.R. 1027, QUIET Act (Reps. Sorensen and Ciscomani)
H.R. 7294, AI for Secure Networks Act (Reps. Menendez and Pfluger)
H.R. 2805, PLAN for Broadband Act (Reps. Walberg and Peters)
H.R. 4950, Data BRIDGE Act (Reps. Houchin and Kelly (IL)

This notice is at the direction of the Chairman. The hearing will be open to the public and press and will be live streamed online at energycommerce.house.gov. If you have any questions concerning the hearing, please contact Noah Jackson with the Committee staff at Noah.Jackson@mail.house.gov. If you have any press-related questions, please contact Daniel Kelly at Daniel.Kelly@mail.house.gov.

Jul 15, 2026

Health

Chairman Griffith Delivers Opening Statement at Subcommittee on Health Markup of Three Bills Combatting Illicit Drug Threats

WASHINGTON, D.C. - Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, delivered the following opening statement at today's markup of three bills.

Subcommittee Chairman Griffith's opening statement as prepared for delivery:

"Today's markup will focus on a few bills that work to combat the illicit drug crisis facing our communities, specifically targeting the growing threat posed by pill presses.

"These bills work together to create regulatory framework that allows DEA to conduct oversight of a closed system of distribution for pill presses and their critical parts-just like we have for controlled substances.

"This system ensures good actors are able to utilize pill presses for legitimate intended uses, while giving DEA the tools to monitor suspicious orders and prevent bad actors from diverting pill presses for the illicit production of counterfeit pills.

"H.R. 5880, the Fight Illicit Pill Presses Act, is led by Representative Hageman from Wyoming, and would establish requirements for serial numbers, record keeping, and transaction reporting for pill presses and their critical parts.

"The Preventing Rogue Equipment for Synthetic Substances (PRESS) Act, H.R. 7184, is led by Representative McDowell from North Carolina.

"It would criminalize the importation of pill press equipment with the intent to illicitly produce a controlled substance.

"H.R. 8005, the Stop Pills that Kill Act, is led by Representative Evans from Colorado.

"This legislation would apply enhanced criminal penalties to those who engage in the illicit manufacture of fentanyl, fentanyl analogs, or fentanyl related substances.

"It would also direct the DEA to establish and implement a comprehensive plan to address the threat of counterfeit pills that contain fentanyl, methamphetamine, or any other illicit synthetic substance.

"I look forward to continuing to work on these policies and bringing them to the full Committee."

Jul 15, 2026

Health

Chairman Griffith Delivers Opening Statement at Subcommittee on Health Hearing on Maintaining U.S. Leadership in Biomedical Innovation

WASHINGTON, D.C. - Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, delivered the following opening statement at today's hearing titled Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advancing U.S. Drug Development.

Subcommittee Chairman Griffith's opening statement as prepared for delivery:

"Today's hearing will examine ways to maintain American leadership in biomedical innovation.

"This hearing is a great opportunity to learn more about what is working, where improvements can be made, and how Congress can ensure FDA continues to serve patients, promote innovation, and maintain our nation's leadership in biomedicine.

"The United States has always been the global leader in biopharmaceutical research and development, and it is important that we remain leaders in this space.

"However, other countries are catching up to the United States.

"It is important for Congress to reexamine our current landscape to ensure we are staying up to date with the latest biopharmaceutical advancements and examine what role Congress could play in making these processes more efficient.

"This Administration has proposed efforts to do so, such as the recent launch of FDA's Operation Trialblazer, announced in June.

"This is an HHS-wide effort that comes in response to the growing competitiveness of the global pharmaceutical landscape which promotes cross-agency collaboration to support research from the earliest stages of innovation.

"Operation Trialblazer provides a set of initiatives and reforms to modernize and accelerate medical product development, aiming to remove the unnecessary hurdles and ambiguity that sometimes hinder patient access to innovative treatments.

"Streamlining clinical trial requirements, encouraging use of modern trial designs and real-world evidence where appropriate, and reducing administrative burden can shorten development timelines and lower costs without compromising science or safety.

"These improvements have the potential to bring new treatments to patients faster, increase participation in clinical research, and make the United States even more attractive for investment in medical breakthroughs.

"It is important that we begin to have these conversations as this Subcommittee looks ahead to FDA's user fee reauthorization next year-especially as initiatives like Operation Trialblazer demonstrate that an approach to maintaining America's competitive edge involves improving the efficiency of drug development.

"For more than three decades, user fee programs have helped provide FDA with the resources to review innovative drugs and medical devices while maintaining the agency's rigorous standards for safety and effectiveness.

"Rather than relying solely on taxpayer dollars, user fees are paid by manufacturers that submit products for review, helping ensure the FDA has the scientific expertise and capacities necessary to keep pace with rapidly advancing medical innovation.

"Ultimately, user fees serve to improve health outcomes for patients.

"Every day that a safe and effective therapy reaches the market is another day that patients living with cancer, rare diseases, or other serious conditions may have access to life-changing or even life-saving treatments.

"The predictability and performance goals established through the user fee agreements have helped reduce review times, improve communication between FDA and product developers, and provide greater standardization throughout the review process.

"However, there is still more work that can be done, and reauthorization is not limited to just extending the status quo.

"Reauthorization gives Congress the opportunity to explore and write legislation so we can continue to work to streamline regulatory processes, reduce unnecessary administrative burden, strengthen communication with product developers, and ensure the agency has the tools it needs to make the best possible use of its resources.

"We can also continue to look for opportunities to modernize clinical trial networks, embedding them into routine care and expanding access to innovative treatments in rural communities.

"Maintaining America's position as the global leader in biomedical innovation requires a regulatory system that is both thorough and efficient.

"I am eager to look for ways that we can help ensure FDA can review drugs in a timely and predictable manner. Not only to expand patient access to innovative treatments, but to also encourage companies to invest, develop, and manufacture domestically.

"Thank you to the witnesses for being here this morning. I look forward to the discussion."

Jul 15, 2026

Commerce, Manufacturing, and Trade

Chairmen Guthrie and Bilirakis Announce Hearing on Legislation to Strengthen Consumer Product and Service Protections

WASHINGTON, D.C. - Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Gus Bilirakis (FL-12), Chairman of the Subcommittee on Commerce, Manufacturing, and Trade, announced a hearing titled Legislative Proposals to Strengthen Consumer Protection in a Changing Marketplace.

"Safe products and transparent marketplaces are necessary components of a strong, vibrant economy," said Chairmen Guthrie and Bilirakis. "This hearing will give us the opportunity to examine legislation that empowers consumers, combats unfair and deceptive practices, and advances safety. We look forward to considering these bills with our colleagues as we work to defend Americans from dangerous goods, fraudulent schemes, and other consumer harms."

Subcommittee on Commerce, Manufacturing, and Trade hearing titled Legislative Proposals to Strengthen Consumer Protection in a Changing Marketplace.

WHAT: Subcommittee on Commerce, Manufacturing, and Trade hearing to consider legislation to strengthen consumer product and service protections.

DATE: Wednesday, July 22, 2026
TIME: 10:15 AM ET
LOCATION: 2123 Rayburn House Office Building

The hearing will focus on the following bills:

H.R. 6832, Packaging and Claims Knowledge (PACK) Act of 2025 (Rep. Weber)
H.R. 7502, Recycled Materials Attribution Act (Reps. Langworthy and Gonzalez)
H.R. 7945, Nitrous Oxide Safety Act of 2026 (Reps. Mullin and Bice)
H.R. 5956, Defending Against Foreign Propaganda Act (Rep. Kean)
H.R. 5967, Strategic Task Force on Scam Prevention Act (Reps. Menendez and Houchin)
H.R. 3875, Transparency in Enforcement, Restricting, and Monitoring of Services (TERMS) Act (Rep. Goldman (TX))
H.R. 3209, App Store Freedom Act (Reps. Cammack and Trahan)
H.R. 2713, Mitigating Automated Internet Networks for (MAIN) Event Ticketing Act (Reps. Harshbarger and Carter (GA))
H.R.___, BOSS and SWIFT Act of 2026 (Rep. Pallone)
H.R.___, Debt Settlement Disclosure Act (Reps. Fry and Peters (CA))
H.R.___, Short Term Rental Sex Offending Disclosure (Rep. Harshbarger)
H.R.___, Stop the Fraud Act (Rep. Lee (FL))

This notice is at the direction of the Chairman. The hearing will be open to the public and press and will be live streamed online at energycommerce.house.gov. If you have any questions concerning the hearing, please contact Jackson Rudden with the Committee staff at Jackson.Rudden@mail.house.gov. If you have any press-related questions, please contact Daniel Kelly at Daniel.Kelly@mail.house.gov.

Jul 15, 2026

Health

Health Subcommittee Advances Three Bills to Safeguard Communities from Existing and Emerging Illicit Drug Threats

WASHINGTON, D.C. - Today, Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, led a markup of three bills aiming to combat the threat of existing and emerging drug threats and safeguarding public health.

"This Health Subcommittee markup is another example of how the House Committee on Energy and Commerce is prioritizing policies to protect our communities from dangerous substances and counterfeit drug-making tools like pill presses," said Chairman Griffith. "I am grateful we advanced such important pieces of legislation to the full Committee and that we have a Congress so dedicated to protecting the public safety of Americans."

Legislative Vote Summary:

H.R. 7184, the PRESS Act, was forwarded to the Full Committee, by voice vote.
H.R. 8005, the Stop Pills That Kill Act, was forwarded to the Full Committee, as amended, by voice vote.
H.R. 5880, the Fight Illicit Pill Presses Act, was forwarded to the Full Committee, by voice vote.

Watch the full markup here.

Below is a key excerpt from today's markup:

Congressman Morgan Griffith (VA-09) on H.R. 8005, the PRESS Act: "The influx of illicit drugs into the U.S. has, in part, been driven by bad actors-I would say in big part-exploiting loopholes within our legal system. Currently, one of those loopholes is the unfettered importation of pill presses and their critical parts-which are, in turn, being utilized for mass production of counterfeit substances. So, as many of us have heard in various testimonies, they will make a pill that they then try to sell as pill 'X', which doesn't have much of a harm to it, but it's laced with fentanyl or some other dangerous substance. And then we have young people who are dying, thinking that they're just getting a little boost for studies or something else. This act would give our federal prosecutors the tools they need to hold the nefarious foreign actors accountable for importing pill presses and pill equipment into the United States with the intent to illicitly produce controlled substances."

Jul 15, 2026

Health

Health Subcommittee Holds Hearing to Examine Ways to Drive Efficiencies Across Early-Stage Clinical Development

WASHINGTON, D.C. - Today, Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, led a hearing titled Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advancing U.S. Drug Development.

"The United States has always been the global leader in biopharmaceutical research and development, and it is important that we remain leaders in this space," said Chairman Griffith. "Maintaining America's position as the global leader in biomedical innovation requires a regulatory system that is both thorough and efficient. I am eager to find ways we can help ensure FDA can review drugs in a timely and predictable manner-not only to expand patient access to innovative treatments, but to also encourage companies to invest, develop, and manufacture domestically."

Watch the full hearing here.

Below are key excerpts from today's hearing:

Congressman Buddy Carter (GA-01): "I practiced pharmacy for over 40 years, and I saw nothing short of miracles as a result of research and development. And we want to continue with that. We want to make sure that we're letting the markets work and that we're letting capital flow to risk and that we're letting science lead. That is extremely important. I do understand and appreciate the point that has been made here about China and about them taking the lead. But we can't beat China by copying China, because China does not operate under the same rules and regulations that we do. We all understand that. We're going to beat them the same way that we beat Europe, and that is by doubling down on what actually made America the leader in the first place: entrepreneurial spirit, access to capital, free markets, and the best science in the world-and I still say we have the best scientists in the world, right here in the United States of America."

Congressman Troy Balderson (OH-12): "Clinical trials produce plenty of data but sponsors frequently report that the process of gathering and submitting this information is still unnecessarily complicated. Where are there opportunities for FDA to leverage digital technologies to reduce administrative burden, improve trial efficiencies, and allow researchers to spend more time developing therapies and less time navigating paperwork?" Dr. Verst: "With regard to the use of real-world evidence, life science models, digital twins, novel trial designs... [these are] absolutely critical. In addition, wearables, the use of patient-reported outcomes, digital connected devices, and reducing the burden on the investigators and patients is just incredibly important. The good news is that those digital data sets actually reduce time, burden, and cost in cleaning data. In fact, that data can be surfaced for early signal detection, thus accelerating development."

Congressman Tom Kean (NJ-07): "My district is home to numerous small, rare disease companies. These constituents and other companies have frequently raised concerns about inconsistency, and even within FDA review divisions. This is a significant source of uncertainty that translates to an unpredictable regulatory environment and disincentivizes investment in areas of unique need. What additional steps can the FDA take to improve consistency among FDA reviews of rare disease products, while also preserving an adaptive framework that acknowledges the unique challenges of rare disease drug development?" Ms. Winckler: "Thank you, and there are a couple of ways-one, I'll say, that the FDA's Rare Disease Innovation Hub has actually been quite helpful in bringing together not only the different product centers at FDA-Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, and Center for Devices and Radiological Health-and stimulating the conversation so that they can have a better understanding of what endpoint might be relevant in a rare disease and how to use that endpoint. There are further opportunities; it comes from greater collaboration and conversation with the patient communities to make sure that the end points that are being pursued are patient-relevant, but then also conversation among the divisions at FDA and explanation where they may diverge."

Jul 15, 2026

Environment

Environment Subcommittee Advances Seven Pieces of Legislation to Support Addressing Harmful Regulations and to Support Recycling

WASHINGTON, D.C. - Yesterday, Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Environment, led a markup of legislation to address harmful regulations on companies and to support their recycling efforts.

“The bills our Environment Subcommittee marked up yesterday support the recovery of critical minerals and materials from domestic sources,” said Chairman Palmer. “Rather than continuing to rely on adversaries such as China that dominate the critical minerals supply chain, we are taking the commonsense steps needed to safeguard our national security.”
Legislative Vote Summary:

H.R. 2140, the Diesel Emissions Reduction Act of 2025, was forwarded to the Full Committee, by voice vote.
H.R. 3194, the Lifting Overburdensome Commerce Obstructions and Motives (LOCOMOTIVES) Act, was forwarded to the Full Committee, by voice vote.
H.R. 9317, the B_uses Utilizing Safety and Environmental Standards (BUSES) Act_, was forwarded to the Full Committee, by voice vote.
H.R. 9615, the Battery Recycling for America's Competitive Economy (BRACE) Act, was forwarded to the Full Committee, as amended, by voice vote.
H.R. 9616, the Environmental Monitoring and Remediation Technology Assessment Initiative (EMRTAI) Act of 2026, was forwarded to the Full Committee, by voice vote.
H.R. 9617, the Coordinating and Harnessing America's Recovery of Minerals (CHARM) Act, was forwarded to the Full Committee, by voice vote.
H.R. 9618, the Diesel Engine Flexibility (DEF) Act, was forwarded to the Full Committee, as amended, by voice vote.

Watch the full markup here.

Below are key excerpts from today's markup:

Congressman Nick Langworthy (NY-23) on H.R. 9317, the Buses Utilizing Safety and Environmental Standards Act: "Buses are one of the safest and most efficient ways to move large numbers of people. They transport children to school, connect rural communities, and support our tourism industry. They move military personnel, and they provide critical transportation for millions of Americans every single year. The rules governing these operators should reflect what actually takes place to operate a bus safely, not create unnecessary obstacles. Here's the problem: buses don't idle because drivers want to. They idle because the job requires it. Before a bus can even begin its route, federal law requires drivers to complete safety inspections. They need to maintain brake pressure, operate wheelchair lifts and other accessibility equipment, and safely board passengers with disabilities. And where I come from in western New York, keeping passengers warm during the winter is often a matter of safety, not convenience."

Congressman Buddy Carter (GA-01) on H.R. 3194, the Lifting Overburdensome Commerce Obstructions and Motives Act: "H.R. 3194 is a commonsense bill created in response to California's attempt to impose zero-emission locomotive mandates that would dramatically increase the prices of goods and have serious consequences for freight rail. This bill will close the loophole which allows the California Air Resources Board to request waivers from EPA that allow the state to issue overreaching mandates. These mandates would empower California to impose its policies on the national rail system and govern interstate commerce. The CARB proposal would effectively ban a large portion of the national locomotive fleet from operating in California. This would mean higher prices for consumers, and it would not lead to cleaner air quality. The fact is that California is simply rushing to green without looking at the real-world consequences of their actions."

Congresswoman Mariannette Miller-Meeks, M.D. (IA-02) on H.R. 9615, the Battery Recycling for America's Competitive Economy Act: "Demand for lithium-ion batteries in the United States has grown exponentially in recent years, in large part due to demand for rechargeable batteries for energy storage systems, electric vehicles, communication devices, and other consumer goods. As more lithium-ion batteries reach the end of their life, the recycling and recovery of critical minerals from these batteries provides a tremendous opportunity for the United States to boost its supply chains for certain critical minerals. Critical minerals such as nickel, cobalt, lithium, and copper can be recovered from lithium-ion batteries. However, end-of-life batteries and scrap materials are largely sent overseas, often to China, for processing. Our subcommittee has heard testimony at two hearings that our own regulatory scheme under the Resource Conservation and Recovery Act, or RCRA, is contributing to these valuable minerals being sent overseas - and to this missed opportunity to recover critical minerals already present in our country."

Jul 14, 2026

Press Release

Energy Subcommittee Advances Six Bills to Support Safe and Reliable Nuclear Power

WASHINGTON, D.C.* - Today, Congressman Bob Latta (OH-05), Chairman of the Subcommittee on Energy, led a markup of six bills.

"In today's markup, the Subcommittee on Energy considered six pieces of legislation to improve the Nuclear Regulatory Commission's licensing process and Department of Energy nuclear reporting, which will help maintain momentum for U.S. nuclear deployment," said Chairman Latta. "A robust and growing American nuclear industry is vital to meet our nation's rapidly increasing energy demand. A resilient nuclear supply chain is critical for U.S. economic, energy and national security."

Legislative Vote Summary:

H.R. 3978, Nuclear REFUEL (Recycling Efficient Fuels Utilizing Expedited Licensing) Act, was forwarded to the Full Committee, as amended, by voice vote.
H.R. 9612, American Enrichment Deployment Act, was forwarded to the Full Committee, by voice vote.
H.R. 5549, Efficient Nuclear Licensing Hearings Act, was forwarded to the Full Committee, by voice vote.
H.R. 9613, Nuclear Advisory Committee Reform Act, was forwarded to the Full Committee, by voice vote.
H.R. 9614, NRC Staff Pay Alignment Act, was forwarded to the Full Committee, by voice vote.
H.R. 9084, Department of Energy Nuclear Transparency Act, was forwarded to the Full Committee, as amended, by voice vote.

Watch the full markup here.
Below are key excerpts from today's markup:

Congresswoman Harshbarger on H.R. 9613, the Nuclear Advisory Committee Reform Act: "There's a new wave of technologies on the horizon that would still benefit from Advisory Committee on Reactor Safeguards independent review and advice. H.R. 9613 preserves the ACRS role and focuses its work where it will provide the greatest value for the NRC and the public. It would amend the Atomic Energy Act to direct that the Advisory Committee on Reactor Safeguards focus on issues that are directly related to reactor design, safety-significant, and novel, and that have not been previously acted upon by the Committee."

Congressman Fry on H.R. 9612, the American Enrichment Deployment Act: "This bill would amend the Atomic Energy Act to remove unnecessary provisions for licensing enrichment facilities, so that the licensing aligns with the more efficient framework for other nuclear fuel cycle facilities-namely uranium conversion and fuel fabrication. All of these fuel cycle facilities are more akin to industrial chemical facilities than to nuclear reactors, and are therefore subject to an efficient, one-step licensing process for the possession and use of the special nuclear material that the NRC regulates."

Congressman Balderson on H.R. 5549, the Efficient Nuclear Licensing Hearings Act: "This bill amends the Atomic Energy Act to remove the requirement for the NRC to expend resources on unnecessary hearings. Under current law, the NRC must hold mandatory, uncontested hearings on applications for construction permits, operating licenses, and licenses to possess or use special nuclear material. Yet, NRC staff and commissioners already offer more than 20 opportunities for the public and affected parties to be heard in the licensing process for new reactors. Removing this mandatory hearing would in no way impact the right of anyone whose interests are affected by the licensing to request a hearing on specific matters."

Jul 14, 2026

Environment

Chairman Palmer Delivers Opening Statement at Subcommittee on Environment Markup on Legislation to Address Harmful Regulations and Support Recycling

WASHINGTON, D.C. - Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Environment, delivered the following opening statement at today's markup of seven bills.

Subcommittee Chairman Palmer's opening statement as prepared for delivery:

"Welcome to today's markup before the House Energy and Commerce Committee's Subcommittee on Environment.

"Today, we will consider seven pieces of legislation, most of which are bipartisan.

"Three bills we will be marking up support the recovery of critical minerals and materials from domestic sources, rather than continuing to rely on adversaries such as China that dominate the critical mineral supply chain.

"H.R. 9615, the Battery Recycling for America's Competitive Economy or 'BRACE' Act, led by Representative Miller-Meeks directs the Environmental Protection Agency to consider modernizing and clarifying its regulation of lithium-ion batteries by updating its regulations implementing the Resource Conservation and Recovery Act. These regulations predate the widespread use of lithium-ion batteries and potentially inhibit the growth of the domestic battery recycling industry.

"H.R. 9616, Environmental Monitoring and Remediation Technology Assessment Initiative or 'EMRTAI' Act, which authorizes a program at EPA to support methods to identify and recover critical materials at contaminated sites, contributing both to the discovery of new domestic sources of critical materials, and remediating contaminated sites.

"Additionally, we will consider H.R. 9617, the Coordinating and Harnessing America's Recovery of Minerals or 'CHARM' Act. This bipartisan bill, which I am proud to lead with Ranking Member Tonko, channels EPA's expertise on materials recovery and recycling into our government-wide efforts to secure our access to critical minerals by directing EPA to develop and execute a National Critical Mineral Recovery Strategy.

"We are also considering four Clean Air Act bills. As we've discussed before, the Clean Air Act has not been meaningfully updated to adjust to our present-day realities. As a result, outdated provisions currently result in overburdensome standards that hamper economic prosperity while doing little to reduce air pollution. The bills we will consider today provide commonsense solutions that update narrow provisions of the Clean Air Act while continuing to protect the environment.

"H.R. 2140, the Diesel Emissions Reduction Act, is sponsored by Rep. Langworthy and Rep. Matsui. This bill reauthorizes through 2029 the DERA grant program, which facilitates updating and replacing old equipment with newer technology or engines, improving air quality while growing the economy.

"H.R. 3194, the LOCMOTIVES Act, is led by Rep. Moolenaar and Rep. Obernolte. This bill amends the Clean Air Act to ensure that locomotive emissions are subject to a uniform federal framework, protecting our national supply chain and preventing increased operation costs from being passed down to consumers.

"H.R. 9317, the BUSES Act, is sponsored by Rep. Langworthy and Rep. Gottheimer. This legislation creates a national minimum standard for bus idling, preventing state and local governments from enforcing bus idling bans less than15 minutes, which will ensure that interstate carriers are not subjected to inconsistent local requirements or bounty-driven enforcement schemes. The up to 15 minutes of idling time is necessary for checks to protect driver and passenger safety, accessibility, and mobility.

"H.R. 9618, the Diesel Engine Flexibility (DEF) Act, is led by Rep. Fedorchak and Rep. Don Davis. This bill provides regulatory certainty by creating a 10-year safe harbor for actions taken relying on EPA guidance relating to diesel exhaust fluid quality monitoring and selective catalytic reduction inducement standards. This bill gives manufacturers, equipment, owners and independent technicians the certainty they need to move goods and protect supply chains.

"I appreciate the work on both sides to get these bills ready for today's markup.

"Thank you and I yield back."